The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, according to a press release from ANI Pharmaceuticals.
The approval updates the warnings and precautions section of the label for Iluvien (fluocinolone acetonide intravitreal implant), which is also indicated for diabetic macular edema in the U.S. Iluvien previously received approval for DME and noninfectious uveitis affecting the posterior segment (NIU-PS) in 17 countries in Europe.
The company aims to initiate marketing